Long-Term Mortality after New-Onset Atrial Fibrillation in COVID-19

Area of Science:

• Cardiology
• Infectious Diseases
• Critical Care Medicine

Background:

• Atrial fibrillation (AF) is a common cardiovascular issue in COVID-19 patients.
• AF may indicate a higher risk of adverse clinical outcomes in COVID-19 cases.
• Understanding the AF-COVID-19 relationship is vital for patient management.

Purpose of the Study:

• To investigate the association between atrial fibrillation (AF) and clinical outcomes in hospitalized COVID-19 patients.
• To assess the impact of new-onset AF on mortality and rehospitalization rates.
• To determine if AF is a risk factor for severe COVID-19 progression.

Main Methods:

• Observational study including all COVID-19 patients hospitalized in 2020.
• Assessment of clinical characteristics, in-hospital, and long-term outcomes (mean follow-up 278 days).
• Analysis of atrial fibrillation (AF) on admission, including new-onset AF, and its correlation with ventilation, ICU transfer, and mortality.

Main Results:

• Out of 646 COVID-19 patients, 116 (18%) had AF on admission, with 34 (29%) being new-onset.
• New-onset AF in COVID-19 patients was linked to a higher likelihood of invasive ventilation (OR: 3.5; p=0.01) and ICU transfer.
• AF did not significantly increase in-hospital or long-term mortality or rehospitalization rates after adjusting for confounders.

Conclusions:

• New-onset atrial fibrillation (AF) in COVID-19 patients is associated with increased need for intensive care and invasive ventilation.
• AF on admission did not elevate in-hospital mortality risk for COVID-19 patients.
• The study suggests AF is a marker for severe COVID-19 but not an independent predictor of mortality.